Long
HGEN: Weekend Before Phase III Data
HGEN has two RCTs with imminent data, one of them the company's own, the other the NIH's ACTIV-5 Trial. The company is preparing to file an EUA for Lenzilumab pending the trials' completion. Announcements are expected in the week starting March 29, two days from now. Nomis Bay, a fund that had held a large stake of HGEN since it was trading in single digits unloaded millions of shares in the weeks leading up to now. The fund still holds between 9% and 10% of the outstanding shares.In conferences throughout March, HGEN executives mainly showcased the potential for Lenz as a COVID therapeutic, and differences between their trial designs and those of other, failed monoclonal antibodies. I hope everyone is sized appropriately, whether long or short. This stock could make some very large moves soon.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.